Severe Asthma Management

Publication Date: October 1, 2019

Key Points

Key Points

Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.

Treatment

...Tre...

Table 1...

...nti-IL-5 strategy as add-on therap...

...that a blood eosinophil cut-point ≥150...

...a blood eosinophil cut-off ≥260 µL...

...sing a FENO cut-off ≥19.5 ppb to id...

...ldren, adolescents and adults with seve...

...suggest a trial of macrolide treatment to...

...inst the use of chronic macrolide treatm...

We suggest dupilumab as add-on ther...


...able 2. Monoclonal Antibodies for Severe Asthm...